5-methoxyindole metabolites of L-tryptophan: Control of COX-2 expression, inflammation and tumorigenesis

Journal of Biomedical Science

Volumn 21, Issue 1, 2014, Pages

  Wu, Kenneth K ^a,b,c   Cheng, Huei Hsuan ^a,b,c   Chang, Tzu Ching ^a,b,c  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

5 hydroxytryptophan; 5 methoxytryptophan; Cancer metastasis; Cyclooxygenase 2; Cytoguardin; Cytokine; Inflammation; Melatonin; Tumorigensis

Indexed keywords

5 HYDROXYINDOLE; 5 HYDROXYTRYPTOPHAN; 5 HYDROXYTRYPTOPHOL; 5 METHOXYINDOLE; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; DRUG METABOLITE; MELATONIN; MITOGENIC AGENT; SEROTONIN; TRYPTOPHAN; UNCLASSIFIED DRUG; 5-METHOXYINDOLE; CYCLOOXYGENASE 2; INDOLE DERIVATIVE; PTGS2 PROTEIN, HUMAN;

CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CELL MIGRATION; CHEMOPROPHYLAXIS; FIBROBLAST; HUMAN; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY CELL; MESENCHYME CELL; METABOLITE; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STIMULATION; TRANSCRIPTION INITIATION; TUMOR INVASION; TUMOR XENOGRAFT; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM;

CARCINOGENESIS; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; INFLAMMATION; MELATONIN; NEOPLASM METASTASIS; NEOPLASMS; SEROTONIN; TRYPTOPHAN;

EID: 84898540187     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-21-17     Document Type: Review

References (53)

1. Inducible cyclooxygenase and nitric oxide synthase. Wu KK, Adv Pharmacol 1995 33 179 207 7495670
2. Cyclooxygenases: structural, cellular, and molecular biology. Smith WL, DeWitt DL, Garavito RM, Annu Rev Biochem 2000 69 145 182 10.1146/annurev. biochem.69.1.145 10966456
3. Macrophages release arachidonic acid, prostaglandin E2, and thromboxane in response to late complement componenets. Hänsch GM, Seitz M, Martinotti G, Betz M, Rauterberg EW, Gemsa D, J Immunol 1984 133 2145 2150 6432907 (Pubitemid 14035323)
4. Vascular myofibroblasts. Lessons from coronary repair and remodeling. Zalewski A, Shi Y, Arterioscler Thromb Vasc Biol 1997 17 417 422 10.1161/01.ATV.17.3.417 9102158 (Pubitemid 27133129)
5. Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. Zucali JR, Dinarello CA, Oblon DJ, Gross MA, Anderson L, Weiner RS, J Clin Invest 1986 77 1857 1863 10.1172/JCI112512 3486886 (Pubitemid 16062640)
6. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. Dayer JM, Beutler B, Cerami A, J Exp Med 1985 162 2163 2168 10.1084/jem.162.6.2163 2999289 (Pubitemid 16149701)
7. Obligatory role of cyclic adenosine monophosphate response element in cyclooxygenase-2 promoter induction and feedback regulation by inflammatory mediators. Schroer K, Zhu Y, Saunders MA, Deng WG, Xu XM, Meyer-Kirchrath J, Wu KK, Circulation 2002 105 2760 2765 10.1161/01.CIR.0000018127.10968.34 12057991 (Pubitemid 34615148)
8. Dynamic regulation of cyclooxygenase-2 promoter activity by isoforms of CCAAT/enhancer-binding proteins. Zhu Y, Saunders MA, Yeh H, Deng WG, Wu KK, J Biol Chem 2002 277 6923 6928 10.1074/jbc.M108075200 11741938 (Pubitemid 34953077)
9. Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. Deng WG, Zhu Y, Wu KK, J Biol Chem 2003 278 4770 4777 10.1074/jbc.M209286200 12471036 (Pubitemid 36800979)
10. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Deng WG, Zhu Y, Wu KK, Blood 2004 103 2135 2142 10.1182/blood-2003-09-3131 14630807 (Pubitemid 38326230)
11. Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. Deng WG, Wu KK, J Immunol 2003 171 6581 6588 14662860 (Pubitemid 37532089)
12. The p300/CBP family: integrating signals with transcription factors and chromatin. Shikama N, Lyon J, La Thange NB, Trends Cell Biol 1997 7 203 236
13. COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective. Hochberg MC, Curr Top Med Chem 2005 5 443 448 10.2174/1568026054201695 15974939 (Pubitemid 40974816)
14. Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed? Lipsky PE, J Rheumatol Suppl 1999 56 25 30 10225537 (Pubitemid 29183023)
15. Cyclooxygenase in biology and disease. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE, FASEB J 1998 12 1063 1073 9737710 (Pubitemid 28418937)
16. The role of COX-2 in intestinal inflammation and colorectal cancer. Wang D, Dubois RN, Oncogene 2010 29 781 788 10.1038/onc.2009.421 19946329
17. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Tsujii M, Kawano S, DuBois RN, Proc Natl Acad Sci USA 1997 94 3336 3340 10.1073/pnas.94.7.3336 9096394 (Pubitemid 27157312)
18. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN, Cell 1998 93 705 716 10.1016/S0092-8674(00)81433-6 9630216 (Pubitemid 28257578)
19. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Gupta RA, Dubois RN, Nat Rev Cancer 2001 1 11 21 10.1038/35094017 11900248 (Pubitemid 33741877)
20. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Ulrich CM, Bigler J, Potter JD, Nat Rev Cancer 2006 6 130 140 10.1038/nrc1801 16491072 (Pubitemid 43361545)
21. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K, Lancet Oncol 2001 2 544 551 10.1016/S1470-2045(01)00488-0 11905709 (Pubitemid 33586867)
22. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW, Science 1997 275 1787 1790 10.1126/science.275.5307. 1787 9065402 (Pubitemid 27136715)
23. Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3beta in gastric cancer cells. Thiel A, Heinonen M, Rintahaka J, Hallikainen T, Hemmes A, Dixon DA, Haglund C, Ristimäki A, J Biol Chem 2006 281 4564 4569 10.1074/jbc.M512722200 16371352 (Pubitemid 43847714)
24. Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Kolligs FT, Bommer G, Göke B, Digestion 2002 66 131 144 10.1159/000066755 12481159 (Pubitemid 36091845)
25. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC, Cancer Res 2003 63 728 734 12566320 (Pubitemid 36158154)
26. Wnt/β-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells. Nuñez F, Bravo S, Cruzat F, Montecino M, De Ferrari GV, PLoS One 2011 6 18562 10.1371/journal.pone. 0018562 21494638
27. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A, Carcinogenesis 2009 30 377 386 10.1093/carcin/bgp014 19136477
28. Multifaceted roles of PGE2 in inflammation and cancer. Nakanishi M, Rosenberg DW, Semin Immunopathol 2013 35 123 137 10.1007/s00281-012-0342-8 22996682
29. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Xia D, Wang D, Kim SH, Katoh H, DuBois RN, Nat Med 2012 18 224 226 10.1038/nm.2608 22270723
30. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS, Science 2005 310 1504 1510 10.1126/science.1116221 16293724 (Pubitemid 41746348)
31. G-protein-coupled receptors and cancer. Dorsam RT, Gutkind JS, Nat Rev Cancer 2007 7 79 94 10.1038/nrc2069 17251915 (Pubitemid 46164746)
32. Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Neil JR, Johnson KM, Nemenoff RA, Schiemann WP, Carcinogenesis 2008 29 2227 2235 10.1093/carcin/bgn202 18725385
33. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Chakraborty C, Exp Cell Res 2003 289 265 274 10.1016/S0014-4827(03)00269-6 14499627 (Pubitemid 37117412)
34. Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. Kim JI, Lakshmikanthan V, Frilot N, Daaka Y, Mol Cancer Res 2010 8 569 577 10.1158/1541-7786.MCR-09-0511 20353998
35. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Mayoral R, Fernández-Martínez A, Boscá L, Martín-Sanz P, Carcinogenesis 2005 26 753 761 10.1093/carcin/bgi022 15661807 (Pubitemid 41214337)
36. Purification and characterization of a cyclooxygenase-2 and angiogenesis suppressing factor produced by human fibroblasts. Deng WG, Saunders M, Gilroy D, He XZ, Yeh H, Zhu Y, Shtivelband MI, Ruan KH, Wu KK, FASEB J 2002 16 1286 1288 12060668
37. Control of cyclooxygenase-2 expression and tumorigenesis by endogenous 5-methoxytryptophan. Cheng HH, Kuo CC, Yan JL, Chen HL, Lin WC, Wang KH, Tsai KK, Guvén H, Flaberg E, Szekely L, Klein G, Wu KK, Proc Natl Acad Sci USA 2012 109 13231 13236 10.1073/pnas.1209919109 22851770
38. Serotonin synthesis, release and reuptake in terminals: a mathematical model. Best J, Nijhout HF, Reed M, Theor Biol Model 2010 7 34 10.1186/1742-4682-7-34
39. Metabolism of serotonin to N-acetylserotonin, melatonin, and 5-methoxytryptamine in hamster skin culture. Slominski A, Baker J, Rosano TG, Guisti LW, Ermak G, Grande M, Gaudet SJ, J Biol Chem 1996 271 12281 12286 10.1074/jbc.271.21.12281 8647827 (Pubitemid 26160891)
40. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Deng WG, Tang ST, Tseng HP, Wu KK, Blood 2006 108 518 524 10.1182/blood-2005-09-3691 16609073 (Pubitemid 44061351)
41. Melatonin-a pleiotropic, orchestrating regulator molecule. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR, Prog Neurobiol 2011 93 350 384 10.1016/j.pneurobio.2010.12.004 21193011
42. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. Mayo JC, Sainz RM, Tan DX, Hardeland R, Leon J, Rodriguez C, Reiter RJ, J Neuroimmunol 2005 165 139 149 10.1016/j.jneuroim.2005. 05.002 15975667 (Pubitemid 40984631)
43. Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. Dong WG, Mei Q, Yu JP, Xu JM, Xiang L, Xu Y, World J Gastroenterol 2003 9 1307 1311 12800246 (Pubitemid 36805674)
44. Melatonin biosynthesis and metabolism in peripheral blood mononuclear leucocytes. Finocchiaro LM, Nahmod VE, Launay JM, Biochem J 1991 280 727 731 1764037
45. Physiological ischemia/reperfusion phenomena and their relation to endogenous melatonin production: a hypothesis. Tan DX, Manchester LC, Sainz RM, Mayo JC, León J, Reiter RJ, Endocrine 2005 27 149 158 10.1385/ENDO:27:2:149 16217128 (Pubitemid 41558447)
46. Melatonin metabolism in the central nervous system. Hardeland R, Curr Neuropharmacol 2010 8 168 181 10.2174/157015910792246164 21358968
47. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Hill SM, Blask DE, Cancer Res 1988 48 6121 6126 3167858 (Pubitemid 18266811)
48. Effects of melatonin on proliferation of cancer cell lines. Papazisis KT, Kouretas D, Geromichalos GD, Sivridis E, Tsekreli OK, Dimitriadis KA, Kortsaris AH, J Pineal Res 1998 25 211 218 10.1111/j.1600-079X.1998.tb00390.x 9885990 (Pubitemid 29029898)
49. Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin. Ram PT, Yuan L, Dai J, Kiefer T, Klotz DM, Spriggs LL, Hill SM, Pineal Res 2000 28 210 218 10.1034/j.1600-079X.2000.280403. x (Pubitemid 30255373)
50. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. Wang J, Xiao X, Zhang Y, Shi D, Chen W, Fu L, Liu L, Xie F, Kang T, Huang W, Deng W, J Pineal Res 2012 53 77 90 10.1111/j.1600-079X.2012.00973.x 22335196
51. Melatonin in cancer management: progress and promise. Jung B, Ahmad N, Cancer Res 2006 66 9789 9793 10.1158/0008-5472.CAN-06-1776 17047036 (Pubitemid 44672026)
52. Coxibs and cardiovascular side-effects: from light to shadow. Dogné JM, Hanson J, Supuran C, Pratico D, Curr Pharm Des 2006 12 971 975 10.2174/138161206776055949 16533164
53. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E, Integr Cancer Ther 2012 11 293 303 10.1177/1534735411425484 22019490